Skip to main content
SpringerLink
Log in

Intensitätsmodulierte fraktionierte Radiotherapie vs. körperstereotaktische Radiotherapie des Prostatakarzinoms (PACE-B) – akute Toxizität aus einer internationalen, randomisierten Phase-III-Nichtunterlegenheitsstudie

Intensity-modulated fractionated radiotherapy vs. stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomized, open-label, phase 3, noninferiority trial

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N (2019) PACE Trial Investigators.Intensity-modulatedfractionatedradiotherapy versus stereotacticbodyradiotherapyforprostatecancer (PACE-B): acutetoxicityfindingsfrom an international, randomised, open-label, phase 3, non-inferioritytrial. Lancet Oncol 20(11):1531–1543. https://doi.org/10.1016/S1470-2045(19)30569-8

    Article  PubMed  PubMed Central  Google Scholar 

  2. https://www.rtog.org/ResearchAssociates/AdverseEventReporting.aspx. Zugegriffen: 05.04.2020

  3. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H (2018) Effectof standard vs dose-escalated radiation therapy forpatientswith intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol 4(6):e180039–14. https://doi.org/10.1001/jamaoncol.2018.0039

    Article  PubMed  PubMed Central  Google Scholar 

  4. Widmark A, Gunnlaugsson A, Beckman L et al (2019) Ultra-hypofractionated versus conventionallyfractionatedradiotherapyforprostatecancer: 5‑year outcomesoftheHYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385–395

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Strahlentherapie & Radioonkologie am Klinikum Coburg, Ketschendorfer Straße 33, 96450, Coburg, Deutschland

    Gerhard G. Grabenbauer

Authors
  1. Gerhard G. Grabenbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerhard G. Grabenbauer.

Ethics declarations

Interessenkonflikt

G.G. Grabenbauer gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Brand DH, Tree AC, Ostler P, van der Voet H et al (2019) PACE Trial Investigators. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20(11):1531–1543. https://doi.org/10.1016/S1470-2045(19)30569-8.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grabenbauer, G.G. Intensitätsmodulierte fraktionierte Radiotherapie vs. körperstereotaktische Radiotherapie des Prostatakarzinoms (PACE-B) – akute Toxizität aus einer internationalen, randomisierten Phase-III-Nichtunterlegenheitsstudie. Strahlenther Onkol 196, 674–675 (2020). https://doi.org/10.1007/s00066-020-01616-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-020-01616-w

Search

Navigation